Abstract CT032: Phase 1/2 trial of the TBL1 inhibitor, tegavivint, in advanced hepatocellular carcinoma (aHCC)

Journal article

Peer reviewed

David Hsieh, Eric X. Chen, Joseph Franses, Z Ian Hu, Lynn Feun, Gentry King, Jimmy Hwang, David Stenehjem, Casey Cunningham and Daneng Li

Cancer research (Chicago, Ill.), Vol.85(8_Supplement_2), pp.CT032-CT032

2025-04-25

Metrics

1 Record Views

Title: Abstract CT032: Phase 1/2 trial of the TBL1 inhibitor, tegavivint, in advanced hepatocellular carcinoma (aHCC)
Creators: David Hsieh - The University of Texas Southwestern Medical Center
Eric X. Chen - Princess Margaret Cancer Centre
Joseph Franses - University of Chicago
Z Ian Hu - The University of Texas MD Anderson Cancer Center
Lynn Feun - University of Miami
Gentry King - Fred Hutch Cancer Center
Jimmy Hwang - Levine Cancer Institute
David Stenehjem
Casey Cunningham
Daneng Li - City Of Hope National Medical Center
Publication Details: Cancer research (Chicago, Ill.), Vol.85(8_Supplement_2), pp.CT032-CT032
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991032662118302976